Merck KGaA Moves MS Hopeful Evobrutinib To Phase III, Plans Pipeline Update

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

Merck KGaA said its second-quarter performance was boosted by its Life Science lab unit and milestone payments from drug development partners and promised analysts a pipeline update next month.

Merrck
German Merck Group Will Hold A Capital Market Day On 11 Sept • Source: Shutterstock

Investors hoping for fresh news on Merck KGaA’s late-stage pipeline were left largely empty-handed when the family-controlled German pharma gave its second-quarter financial update on 8 September, which saw earnings in the period rise slightly more than market forecasts due in part to strong sales growth at the Darmstadt-based group’s Life Science lab supplies unit and milestone payments from drug development partners GlaxoSmithKline PLC and Pfizer Inc..

Within Merck’s Healthcare segment, good performances from the diabetes drug Glucophage (metformin), especially in Asia, and cancer drug Erbitux (cetuximab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains